When is switching warranted among biologic therapies in rheumatoid arthritis?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
When is switching warranted among biologic therapies in rheumatoid arthritis?
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 12, Issue 3, Pages 319-333
Publisher
Informa UK Limited
Online
2012-07-20
DOI
10.1586/erp.12.27
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach
- (2011) Susanne Schmitz et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
- (2011) M. M. Soliman et al. ANNALS OF THE RHEUMATIC DISEASES
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
- (2011) Regina Rendas-Baum et al. ARTHRITIS RESEARCH & THERAPY
- Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis
- (2010) D. J. Harrison et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
- (2010) D. Salmon-Ceron et al. ANNALS OF THE RHEUMATIC DISEASES
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
- (2010) Peter C Taylor CURRENT OPINION IN PHARMACOLOGY
- Dealing with immunogenicity of biologicals: assessment and clinical relevance
- (2010) Gerrit J Wolbink et al. CURRENT OPINION IN RHEUMATOLOGY
- Sequential use of biologic therapy in rheumatoid arthritis
- (2010) Maya H Buch CURRENT OPINION IN RHEUMATOLOGY
- Lymphoma, rheumatoid arthritis, and TNFα antagonists
- (2010) Xavier Mariette JOINT BONE SPINE
- To switch or to change class—the biologic dilemma in rheumatoid arthritis
- (2010) Edith Villeneuve et al. Nature Reviews Rheumatology
- Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
- (2010) Johan Askling et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The effectiveness of anti-TNF- therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis
- (2010) S. Lloyd et al. RHEUMATOLOGY
- Transmembrane TNF- : structure, function and interaction with anti-TNF agents
- (2010) T. Horiuchi et al. RHEUMATOLOGY
- TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice
- (2009) Antonio Marchesoni et al. Annals of the New York Academy of Sciences
- Ultrasound measurement of the acromioclavicular joint
- (2009) A P Rozin ANNALS OF THE RHEUMATIC DISEASES
- Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
- (2009) X Mariette et al. ANNALS OF THE RHEUMATIC DISEASES
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
- (2009) D E Furst et al. ANNALS OF THE RHEUMATIC DISEASES
- Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
- (2009) A Finckh et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
- (2009) W. G. Dixon et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
- (2009) Sophie Martin Du Pan et al. ARTHRITIS AND RHEUMATISM
- Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?
- (2009) Johan Askling et al. ARTHRITIS AND RHEUMATISM
- Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry
- (2009) F. Tubach et al. ARTHRITIS AND RHEUMATISM
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
- (2009) Merete Lund Hetland et al. ARTHRITIS AND RHEUMATISM
- Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population
- (2009) Daniel A. Ollendorf et al. CLINICAL THERAPEUTICS
- Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
- (2009) Anja Strangfeld JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
- (2009) Josef S Smolen et al. LANCET
- Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
- (2009) Andrea Rubbert-Roth et al. ARTHRITIS RESEARCH & THERAPY
- Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study
- (2008) M H Buch et al. ANNALS OF THE RHEUMATIC DISEASES
- The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
- (2008) M Schiff et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
- (2008) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
- The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study
- (2008) Marte Schrumpf Heiberg et al. ARTHRITIS AND RHEUMATISM
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
- (2008) Kenneth G. Saag et al. ARTHRITIS AND RHEUMATISM
- Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis
- (2008) Karin Laas et al. CLINICAL RHEUMATOLOGY
- Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis
- (2008) Anthony Russell et al. CLINICAL RHEUMATOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started